In this context, the cytolytic activity of these peptide-specific CTLs against tumor cells of HLA-A*03:01+ patients with EBV-associated PTLD should additionally be reaffirmed in future studies. This evidence concerns the gene HLA-A and post-transplant lymphoproliferative disease.